Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension

– First and Only Once-Daily, Fixed-Dose Combination of aProstaglandin Analog and a Rho Kinase (ROCK) Inhibitor – – Rocklatan™ Demonstrated Statistical Superiority overWidely-Prescribed First-Line Agent Latanoprost – Aerie Pharmaceuticals, Inc. […]

Companies Reporting Earnings 2/13/2019

When: February 13, 2019 all-day

Companies Reporting Earnings 2/13/2019 Symbol Company Earnings Call Time EPS Estimate $ARI Apollo Commercial Real Estate Finance Inc After Market Close 0.46 $NLY Annaly Capital Management Inc After Market Close[…]